chemXplore tracks 3 projects in Korea (South), of which 3 are active.
Of the active ones, 2 expansion.
The dates themselves, per project, are for subscribers.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
EU launches anti-dumping probe after PVC imports doubled in 12 months; industry urges faster provisional measures, safeguards and more DG Trade resources to protect European production.
Wholly owned Korea subsidiary to secure marketing authorizations and build phased in‑house sales for pipeline drugs including sparsentan and NXT007.
Develop next‑generation ABS/EP composites, expand PCR material use for interior/exterior parts, and run joint R&D and feasibility studies.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
KRW 480 billion investment for a 450,000 t/yr continuous galvanizing line at Gwangyang; EAF‑linked lower‑carbon, extra‑wide products and AI/robotics for quality and safety.
KRW 160 billion of third-generation high-density LFP cathode to be delivered 2026–2028 for ESS cells at Seosan and Georgia plants.
Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.
World-first mass-production 4µm unstretched PI film matches mechanical, thermal and adhesion performance of standard 12.5µm film at about one-third the thickness.
